Putcha L, Cintrón N M, Tsui J, Vanderploeg J M, Kramer W G
KRUG International, Techhology Life Sciences Division, Houston, Texas 77058.
Pharm Res. 1989 Jun;6(6):481-5. doi: 10.1023/a:1015916423156.
The pharmacokinetics and bioavailability of scopolamine were evaluated in six healthy male subjects receiving 0.4 mg of the drug by either oral or intravenous administration. Plasma and urine samples were analyzed using a radioreceptor binding assay. After iv administration, scopolamine concentrations in the plasma declined in a biexponential fashion, with a rapid distribution phase and a comparatively slow elimination phase. Mean and SE values for volume of distribution, systemic clearance, and renal clearance were 1.4 +/- 0.3 liters/kg, 65.3 +/- 5.2 liters/hr, and 4.2 +/- 1.4 liters/hr, respectively. Mean peak plasma concentrations were 2909.8 +/- 240.9 pg/ml following iv administration and 528.6 +/- 109.4 pg/ml following oral administration. Elimination half-life of the drug was 4.5 +/- 1.7 hr. Bioavailability of the oral dose was variable among subjects, ranging between 10.7 and 48.2%. The variability in absorption and poor bioavailability of oral scopolamine indicate that this route of administration may not be reliable and effective.
在六名健康男性受试者中评估了东莨菪碱的药代动力学和生物利用度,这些受试者通过口服或静脉注射接受0.4毫克该药物。使用放射受体结合测定法分析血浆和尿液样本。静脉注射后,血浆中东莨菪碱浓度呈双指数下降,有快速分布相和相对缓慢的消除相。分布容积、全身清除率和肾清除率的均值和标准误分别为1.4±0.3升/千克、65.3±5.2升/小时和4.2±1.4升/小时。静脉注射后平均血浆峰浓度为2909.8±240.9皮克/毫升,口服后为528.6±109.4皮克/毫升。该药物的消除半衰期为4.5±1.7小时。口服剂量的生物利用度在受试者之间存在差异,范围在10.7%至48.2%之间。口服东莨菪碱吸收的变异性和较差的生物利用度表明这种给药途径可能不可靠且无效。